Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells

Brain Research

Volumn 1344, Issue , 2010, Pages 25-33

  Tasaki, Yoshikazu ^a   Omura, Tomohiro ^a   Yamada, Takehiro ^a   Ohkubo, Tomoko ^a   Suno, Manabu ^a   Iida, Shinya ^a   Sakaguchi, Tomoki ^a   Asari, Masaru ^a   Shimizu, Keiko ^a   Matsubara, Kazuo ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Akt; Meloxicam; MPP+; Neuroprotection; NSAID; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CAY 10404; CYCLOOXYGENASE 2 INHIBITOR; ETACRYNIC ACID; IBUPROFEN; INDOMETACIN; MELOXICAM; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ROTENONE; SYNAPTOPHYSIN; TUNICAMYCIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DAMAGE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG SPECIFICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL LINE, TUMOR; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; NEUROBLASTOMA; NEUROTOXINS; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; THIAZINES; THIAZOLES; TIME FACTORS;

EID: 77953912213     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.04.085     Document Type: Article

References (31)

1. Alique M., Herrero J.F., and Lucio-Cazana F.J. All-trans retinoic acid induces COX-2 and prostaglandin E2 synthesis in SH-SY5Y human neuroblastoma cells: involvement of retinoic acid receptors and extracellular-regulated kinase 1/2. J. Neuroinflammation (2007) 10.1186/1742-2094-4-1
2. +: differential requirement for neuronal cyclooxygenase activity. J. Neurosci. Res. 81 (2005) 121-131
3. Cassarino D.S., Halvorsen E.M., Swerdlow R.H., Abramova N.N., Parker Jr. W.D., Sturgill T.W., and Bennett Jr. J.P. Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-kappaB in cellular models of Parkinson's disease. J. Neurochem. 74 (2000) 1384-1392
4. Chen H., Zhang S.M., Hernan M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., Speizer F.E., and Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60 (2003) 1059-1064
5. Chiba K., Trevor A., and Castagnoli Jr. N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120 (1984) 574-578
6. Cleeter M.W., Cooper J.M., and Schapira A.H. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58 (1992) 786-789
7. Ehringer H., and Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin. Wochenschr. 38 (1960) 1236-1239
8. Fall C.P., and Bennett Jr. J.P. Characterization and time course of MPP+-induced apoptosis in human SH-SY5Y neuroblastoma cells. J. Neurosci. Res. 55 (1999) 620-628
9. Fahn S., and the Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J. Neurol. 252 suppl 4 (2005) IV37-IV42
10. Habeeb A.G., Praveen-Rao P.N., and Knaus E.E. Design and syntheses of diarylisoxazoles: novel inhibitors of cyclooxygenase-2 (COX2) with analgesic-antiinflammatory activity. Drug Dev. Res. 51 (2000) 273-286
11. +)- and nerve growth factor-induced changes in pro- and anti-apoptotic signaling pathways in SH-SY5Y neuroblastoma cells. Brain Res. 952 (2002) 98-110
12. Hernan M.A., Logroscino G., and Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66 (2006) 1097-1099
13. Heumann R., Goemans C., Bartsch D., Lingenhohl K., Waldmeier P.C., Hengerer B., Allegrini P.R., Schellander K., Wagner E.F., Arendt T., Kamdem R.H., Obst-Pernberg K., Narz F., Wahle P., and Berns H. Transgenic activation of Ras in neurons promotes hypertrophy and protects from lesion-induced degeneration. J. Cell Biol. 151 (2000) 1537-1548
14. Koller W.C., and Tse W. Unmet medical needs in Parkinson's Disease. Neulorogy 62 (2004) S1-S8
15. Kurkowska-Jastrzebska I., Babiuch M., Joniec I., Przybylkowski A., Czlonkowski A., and Czlonkowska A. Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int. Immunopharmacol. 2 (2002) 1213-1218
16. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., and Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5 (1999) 1403-1409
17. Marek K., Jennings D., and Seibyl J. Do dopamine agonists or levodopa modify Parkinson's disease progression?. Eur. J. Neurol. 9 Suppl 3 (2002) 15-22
18. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
19. Newhouse K., Hsuan S.L., Chang S.H., Cai B., Wang Y., and Xia Z. Rotenone-induced apoptosis is mediated by p38 and JNK MAP kinases in human dopaminergic SH-SY5Y cells. Toxicol. Sci. 79 (2004) 137-146
20. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., and Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57 (2005) 168-175
21. Saporito M.S., Brown E.M., Miller M.S., and Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. 288 (1999) 421-427
22. Shimoke K., and Chiba H. Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease. J. Neurosci. Res. 63 (2001) 402-409
23. Sian J., Gerlach M., Youdim M.B., and Riederer P. Parkinson's disease: a major hypokinetic basal ganglia disorder. J. Neural Transm. 106 (1999) 443-476
24. Timmons S., Coakley M.F., Moloney A.M., and Neill C.O. Akt signal transduction in Parkinson's disease. Neurosci. Lett. 467 (2009) 30-35
25. Teismann P., and Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39 (2001) 167-174
26. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl Acad. Sci. USA 100 (2003) 5473-5478
27. Ton T.G., Heckbert S.R., Longstreth Jr. W.T., Rossing M.A., Kukull W.A., Franklin G.M., Swanson P.D., Smith-Weller T., and Checkoway H. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov. Disord. 21 (2006) 964-969
28. Tsuruta F., Sunayama J., Mori Y., Hattori S., Shimizu S., Tsujimoto Y., Yoshioka K., Masuyama N., and Gotoh Y. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J. 23 (2004) 1889-1899
29. Tulasne D., and Foveau B. The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ. 15 (2008) 427-434
30. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., and Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl Acad. Sci. USA 96 (1999) 7563-7568
31. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 150 (2007) 936-976